Human papillomavirus-related tumors in HIV

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 463-468

  Palefsky, Joel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anogenital cancers; Highly active antiretroviral therapy; HIV; Human papillomavirus

Indexed keywords

ANTIRETROVIRUS AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN C; WART VIRUS VACCINE;

ANAL INTRAEPITHELIAL NEOPLASIA TYPE 3; ANUS CANCER; CANCER RADIOTHERAPY; CANCER SCREENING; CERVICAL INTRAEPITHELIAL NEOPLASIA TYPE 3; CONDYLOMA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENITAL TRACT CANCER; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS LOAD; WART VIRUS;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 33746922703     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239885.13537.36     Document Type: Review

References (36)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044. This article describes the total global burden of cancer, including those attributable to different infectious agents. It places HPV-related cancers in context and shows how they comprise a large proportion of cancers worldwide.
2. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120-2129.
3. Moodley JR, Hoffman M, Carrara H, et al. HIV and preneoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006; 6:135. This paper provides data comparing the risk of CIN and cervical cancer in HIV-positive and HIV-negative women in South Africa.
4. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985-990. This paper is important because it describes data from one of the few cancer-HIV registry matches in Africa, and may provide a better estimate of cancer risk among HIV-positive individuals than case-control studies.
5. Palefsky J. Biology of HPV in HIV Infection. Adv Dent Res 2006; 19:99-105.
6. Hawes SE, Critchlow CW, Sow PS, et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst 2006; 98:100-109. This paper is one of only a few to describe the risk of CIN in the setting of HIV-2 infection, which has a more indolent course than HIV-1, and highlights the role of HPV persistence as the primary risk factor for incident CIN.
7. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586. This is the first paper to demonstrate the role of reactivation of HPV types in HIV-positive women in detection of new HPV types in this population, and strongly supports the existence of a latent HPV state.
8. + levels.
9. Heard I, Potard V, Foulot H, et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005; 39:412-418. This paper describes the increased risk recurrence after therapy for CIN among HIV-positive women, but demonstrates a beneficial effect of HAART to reduce recurrence.
10. •], shows a beneficial effect of HAART to reduce recurrence.
11. Denny L, Walraven S, Myer L, et al. Management of cervical disease in HIV-infected women. Gynecol Oncol 2005; 99 (3 Suppl 1):S14-S15.
12. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-1071.
13. Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther 2005; 18:67-76.
14. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 2005; 92:1133-1136. This is one of few papers to document progression of AIN 3 to invasive anal cancer.
15. Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. Int J Colorectal Dis 2005:1-5, [ Epub ahead of print] This paper documents the increased risk of anal cancer in individuals with immunosuppression other than that related to HIV.
16. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 2005; 97:896-905. This is the first paper to describe the prevalence of anal cytologic abnormalities in a large multisite study of HIV-negative MSM in the US, spanning a wide age range. The results demonstrate a steady prevalence of disease across age ranges, differing from the natural history of CIN in women.
17. Kreuter A, Brockmeyer NH, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol 2005; 52:603-608. This is a study of European MSM, confirming earlier studies of American HIV-positive MSM documenting a high rate of anal HPV infection and AIN.
18. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005; 48:1042-1054. This is the first study of infrared coagulation for the treatment of high-grade AIN and documents its potential utility for this purpose.
19. Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum 2005; 48:444-450. This paper documents the use of topical 5-fluorouracil to treat extensive anal Bowen's disease.
20. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005; 40:451-455. This paper describes an increased incidence of anal cancer in the HAART era. It shows how the male to female ratio has changed from the pre-HAART era, with diagnosis at an earlier age than in the pre-HAART era.
21. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:14-19.
22. Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314-320. This paper demonstrates the increased incidence of anal cancer in the HAART era among men with AIDS.
23. + or HIV viral load, implying that HAART-related improvement in these measures may not reduce the incidence of anal cancer.
24. Wilkin TJ, Palmer S, Brudney KF, et al. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 2004; 190:1685-1691.
25. Palefsky JM, Holly EA, Efird JT, et al. Anal intraepithelial neoplasia in the HAART era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-1414. This paper documents the high prevalence of AIN among MSM on HAART. Being on HAART was one of the strongest risk factors for detection of AIN and the data suggest that HAART will have a limited impact on reducing the incidence of anal cancer.
26. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48:1176-1181. This paper is one of the first to show that HIV-positive individuals on HAART may better tolerate a full course of chemoradiation therapy for anal cancer than those treated in the pre-HAART era.
27. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13-22.
28. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278. This was the first paper to demonstrate efficacy of the prophylactic quadrivalent human papillomavirus to prevent infection with HPV16 and HPV18, as well as incident CIN 2 or 3 associated with these types. Infection and disease associated with nonvaccine HPV types was not affected.
29. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255. The duration of response to the HPV vaccine is not yet known. This paper documented elevated antibody titers and continued protection against persistent HPV16 or HPV18 infection and associated CIN 2 or 3 for a follow-up period of up to 4. 5 years. The paper also described evidence for cross-protection against the oncogenic types and to a lesser extent, HPV31. This was the first evidence to suggest that the HPV16 and HPV18 bivalent vaccine may confer broader cross-protection than HPV16 or HPV18 alone.
30. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765.
31. Viscidi RP, Ahdieh-Grant L, Clayman B, et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003; 187:194-205.
32. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005; 14:283-288. This paper showed that HPV seropositivity in HIV-positive women was not associated with reduced incident detection of the HPV types to which they were seropositive, implying that natural infection produces antibody titers too low to confer protection.
33. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-236.
34. Gagne SE, Jensen R, Polvi A, et al. High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. J Acquir Immune Defic Syndr 2005; 40:182-189. This is one of few papers to study genetic changes in AIN, showing increased changes with increased grade of disease and confirming earlier results showing the importance of amplification of chromosome 3q.
35. Zhang J, Martins CR, Fansler ZB, et al. DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res 2005; 11:6544-6549. This is the first paper to address epigenetic changes in AIN and anal cancer and shows a potentially important role for these changes in disease pathogenesis.
36. Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006; 20:1151-1155. This was a phase I safety study of a therapeutic vaccine against high-grade AIN in HIV-positive individuals. The vaccine was shown to be safe and led to clearance of anal HPV infection in a subset of individuals who showed partial or complete disease regression.